The Germany-based company has now raised more than $190m since it was founded, with the Swisscom-backed Mona Lisa Fund among existing backers.

Swisscom-backed biopharmaceutical company Immatics Biotechnologies closed its series D round yesterday at €34m ($46m) after raising a second tranche worth €22m ($29.8m).

Germany-based Immatics secured the funds from existing investors including venture capital firms Dievini Hopp Biotech and Wellington Partners, and AT Impf, the family office of Andreas and Thomas Struengmann.

All three investors participated in Immatics’ $75m series C round in 2010 along with Mona Lisa Fund, the venture firm in which telecommunications company Swisscom is the sole limited…